Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX® B/E prime-boost HIV-1 vaccine trial in Thailand
Authors: Chitraporn Karnasuta
Robert M. Paris
Josephine H. Cox
Sorachai Nitayaphan
Punnee Pitisuttithum
Prasert Thongcharoen
Arthur E. Brown
Sanjay Gurunathan
James Tartaglia
William L. Heyward
John G. McNeil
Deborah L. Birx
Mark S. De Souza
Armed Forces Research Institute of Medical Sciences, Thailand
U.S. Military HIV Research Program
Mahidol University
Sanofi Pasteur SA
Aventis Pasteur
VaxGen, Inc.
Keywords: Biochemistry, Genetics and Molecular Biology;Immunology and Microbiology;Medicine;Veterinary
Issue Date: 31-Mar-2005
Citation: Vaccine. Vol.23, No.19 (2005), 2522-2529
Abstract: Antibody-dependent cell-mediated cytotoxicity (ADCC) was assessed in volunteers participating in an ALVAC-HIV (vCP1521)/AIDSVAX® B/E gp120 prime-boost vaccine trial in Thailand. ADCC activity was measured using chromium release from gp120 subtype B- and CRF01_AE-coated targets in 95 vaccinees and 28 placebo recipients. There was a significant difference in the magnitude of the ADCC response to both targets between vaccinees and placebo recipients. The frequency of responders to subtype B and to CRF01_AE was 96% and 84% in the vaccine group versus 11% and 7% in the placebo group. The results demonstrate that this HIV vaccine is a potent inducer of ADCC activity and may be an additional protection of this prime-boost vaccine in preventing HIV disease.
ISSN: 0264410X
Appears in Collections:Scopus 2001-2005

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.